UCB's publications

With scientific excellence at the forefront of our activities, our scientists actively publish in key journals. Below is a selection from our different areas of expertise.

Annacker O, Coombes J L, Malmstrom V et al. (2005) Essential role for CD103 in the T cell-mediated regulation of experimental colitis. Journal of Experimental Medicine. 202(8):1051-1061

Crabbe T, Welham M J, Ward S G. (2007) The PI3K inhibitor arsenal: choose your weapon!. Trends in Biochememical Sciences. 32(10):450-456

Demaude, T, Knerr, L, Pasau, P. (2004) New synthetic pathway to diverse 2-substituted quinolines based on a multicomponent reaction: solution-phase and solid-phase applications. Journal of Combinatorial Chemistry 6, 768

Derkinderen P, Scales T M E, Hanger D P et al. (2005) Tyrosine 394 is phosphorylated in Alzheimer's paired helical filament tau and in fetal tau with c-Abl as the candidate tyrosine kinase. Journal of Neuroscience; 25(28):6584-6593

Lynch, B A, Lambeng, N, Nocka, K, Kensel-Hammes, P, Bajjalieh, S.M, Matagne, A and Fuks B. (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proceedings of the National Academy of Sciences USA, 101:9861-9866

Lynch BA, Matagne A, Brännström A, von Euler A, Jansson M, Hauzenberger E, Söderhäll JA. (2008) Visualization of SV2A conformations in situ by the use of Protein Tomography. Biochemical and Biophysical Research Communications 375(4):491-5

Kasprowicz D J, Droin N, Soper D M, Ramsdell F, Green D R, Ziegler S F. (2005) Dynamic regulation of FoxP3 expression controls the balance between CD4+T cell activation and cell death. European Journal of Immunology. 2005; 35(12):3424-3432

Kelm, S., Shi, J. and Dean C.M. (2010) MEDELLER: Homology-based coordinate generation for membrane proteins, Bioinfomatics (Advance access, October 5)

Klitgaard, H and Verdru, P. (2007) Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opinion on Drug Discovery, 2(11):1537-1545

Meissner, W, Ravenscroft, P, Reese, R, Harnack, D, Morgenstern, R, Kupsch, A, Klitgaard, H, Bioulac, B, Gross, C.E, Bezard, E and Boraud T. (2006) “Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine”. Neurobiology of Disease, 22:586-598

Niespodziany, I, Klitgaard, H and Margineanu, D-G. (2001) Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurons of rat hippocampal slices. Neuroscience Letters, 306(1-2):5-8

Smith E L, Finney H M, Nesbitt A M, Ramsdell F, Robinson M K. (2006) Splice variants of human FOXP3 are functional inhibitors of human CD4 + T-cell activation. Immunology 119(2):203-211

Wolff et al. (2003), Comparative study of membrane potential-sensitive fluorescent probes and their use in ion channel screening assays, Journal of Biomolecular Screening 8(5): 533-543

Zhu, W; Mena, M; Jnoff, E; Sun, Na; Pasau, P; Ghosez, L Angew. (2009) ChemInform Abstract: Multicomponent Reactions for the Synthesis of Complex Piperidine Scaffolds. ChemInform, 48, 1

Zona, C, Niespodziany, I. Marchetti, C, Klitgaard, H, Bernardi, G and Margineanu, D-G (2001) Levetiracetam does not modulate neuronal voltage-gated Na+ and T-type Ca2+ currents. Seizure 10(4):279-286

Zou, D; Zhai, H-X; Eckman, J; Higgins, P; Gillard, M; Knerr, L; Carre, S; Pasau, P; Collart, P; Grassi; Libertine, L; Nicolas, J.-M; Schwartz, C.E. (2007) Novel, Acidic CCR2 Receptor Antagonists: From Hit to Lead. Letters in Drug Design & Discovery 4, 185.